SSY GROUP announced its full-year financial results for the fiscal year ended December 31, 2025. During 2025, the group faced multiple pressures including shrinking demand, deepening policy reforms, and intensified industry competition, leading to unprecedented downward pressure on its key economic indicators. Confronted with these challenges, the group actively transformed pressure into motivation, driving the company forward through innovation and pragmatic efforts.
For the full year of 2025, the group achieved sales revenue of approximately RMB 3.812 billion, a decrease of 27.6% year-on-year. In Hong Kong dollar terms, full-year sales revenue was approximately HK$4.165 billion, down 27.8% compared to the previous year. The gross profit margin for the same period was approximately 41.6%, a decline of 8.8 percentage points. Net profit attributable to shareholders was approximately HK$471 million, representing a decrease of 55.6%.
The board of directors has resolved to distribute a final dividend of HK$0.03 per share on June 4, 2026, to shareholders registered in the company's register of members on May 21, 2026. The total dividend for the full year amounts to HK$0.08 per share, a reduction of 54.3% year-on-year.
Throughout the year, the group continuously enhanced market accessibility for its products. In 2025, despite unfavorable factors, the group effectively coordinated the approval of new products with their market entry, actively participating in various drug tendering activities, including national centralized procurement programs, follow-up procurements, and inter-provincial alliance and local tenders. The group successfully achieved market access for 52 specifications across 42 generic names during the year.
Furthermore, the group participated in thousands of drug tenders, including national procurement follow-ups, inter-provincial and local joint procurements, and hospital tenders. It demonstrated strong performance and secured significant wins in major tenders, further solidifying its market foundation in key regions and creating conditions for improved product accessibility.
Additionally, the group's portfolio of drugs listed in the National Reimbursement Drug List continued to expand. The 2025 updated National Reimbursement Drug List newly included Calcium Gluconate and Sodium Chloride Injection, bringing the group's total number of listed varieties to 201.
Comments